58 results about "Pulmonary edema" patented technology

The invention belongs to the technical field of medicines, and discloses a common goldenrop decoction active ingredient composition and application thereof in prevention and treatment of human respiratory syncytial virus. The invention relates to application of an active ingredient composition (isoliquiritigenin, baicalein, 6-shogaol, schisandrin B, ferulic acid and methyl salicylate) of Xiaochaihu decoction and / or a derivative of the active ingredient or a pharmaceutically acceptable salt thereof in preparation of medicines for preventing, relieving and / or treating RSV (Respiratory Syndrome Virus) infectious diseases. According to the invention, by establishing a mouse RSV infection model, the effect and the action mechanism of the composition in preventing and treating RSV infection are evaluated. Results show that each dose group can inhibit replication of RSV in mouse lung tissues, relieve pulmonary edema, improve pathological changes of the lung, inhibit expression of inflammatory factors and improve humoral immunity, and the effect is equivalent to that of ribavirin. The radix bupleuri granules have better effects on relieving pulmonary edema and inhibiting virus proliferation compared with small radix bupleuri granules. The composition of the effective components of the common goldenrop can provide a new drug treatment scheme for clinical RSV infectious diseases.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating acute respiratory distress syndrome and a preparation and a preparation method thereof, and the traditional Chinese medicine composition is prepared from the following raw materials: 12-30g of ginseng, 6-30 parts of rheum officinale, 9-30 parts of salvia miltiorrhiza and 3-15 parts of semen lepidii. Pharmacological experiments prove that the traditional Chinese medicine composition can improve lung inflammation infiltration to different degrees, improve lung tissue structure disorder and relieve pulmonary edema, and the clinical death rate is remarkably reduced in clinical application; the prepared preparation, especially granules, can be stored for 36 months for a long time, and is suitable for further industrial mass production.

The present invention relates to the field of medicines and relates to a fused five-membered and six-membered heterocyclic compound, a preparation method therefor, and a use thereof in the field of pharmaceuticals. Specifically, the present invention provides a compound having a structure represented by formula (I), or a stereoisomer, a tautomer, a solvate, a metabolite, a pharmaceutically acceptable salt, or a prodrug thereof. The compound and a pharmaceutical composition thereof of the present invention can be used for preparing a medicament for treating HIF-2α-mediated related diseases, such as renal anemia, chronic kidney disease, chronic metabolic disease, neurodegenerative disease, infection, inflammatory disease, pulmonary edema, and acute respiratory distress syndrome.

A use of a sulfonamide compound represented by formula (I) or a pharmaceutical composition comprising same in the preparation of a drug for treating pulmonary edema.

The invention belongs to the field of respiratory system disease treatment, and provides application of a gymnadenia conopsea extract in preparation of a medicine for treating or preventing pulmonary edema. The embodiment of the invention proves that both the gymnadenia conopsea alcohol extract and the gymnadenia conopsea water extract can effectively improve indexes such as pulmonary edema respiratory rate, minute ventilation volume, rising tidal volume, inspiration peak flow, expiration peak flow and the like, and improve arterial blood-gas indexes and inflammatory factor level in alveolar lavage fluid. The invention provides the application of the gymnadenia conopsea alcohol extract and the gymnadenia conopsea water extract in the medicine for treating or preventing lung diseases, especially pulmonary edema for the first time, the traditional medicine gymnadenia conopsea is fully developed and utilized, and a safe and effective means is provided for treating the critical disease pulmonary edema.

To provide a type C natriuretic peptide and a method for treating acute lung injury. [Solution] This disclosure relates to the treatment of lung, liver, and / or kidney disorders by administering therapeutically effective doses of (ultra)long-acting C-type natriuretic peptide (CNP), CNP derivatives, (ultra)long-acting CNP derivatives, or (ultra)long-acting CNP receptor (NPRB) agonists to subjects in need. This disclosure also relates to the treatment of non-cardiovascular causes of hypoxia, elevated inflammatory cell levels in the lungs, pulmonary edema, sepsis, bacteremia, fibrosis in general, and / or interstitial lung disease using these.

A deep learning system that detects and counts A-lines in lung images obtained with the VSI protocol, allowing untrained personnel to perform scans. By segmenting and counting A-lines, the system distinguishes between healthy lungs and conditions such as pneumonia or edema, without a specialist intervention. The Attention U-Net architecture improves accuracy, and A-line counting provides quantitative data for diagnostics. This approach aims to expand access to diagnostics, specially in resource-limited areas, offering a scalable solution for early detection of lung disease.

The invention belongs to the technical field of biological medicines, and particularly relates to a honeysuckle total extract inhalation solution as well as a preparation method and application thereof. According to the invention, the honeysuckle total extract with poor water solubility, phospholipid and chitosan are innovatively and directionally assembled into the chitosan-phospholipid nanoparticles with uniform structure, and the nanoparticles are prepared by adopting a microfluidic technology. The strategy significantly improves the water solubility and stability of the honeysuckle total extract, and successfully prepares an inhalation solution suitable for pulmonary administration based on the nanoparticle dispersion system. The obtained preparation has the characteristics of high physical stability and good bioavailability potential. The honeysuckle total extract inhalation solution provided by the invention can effectively relieve the pathological process of the pyotoxic pneumonia through multiple mechanisms of remarkably inhibiting lung inflammatory response, relieving pulmonary edema, protecting the structural integrity of pulmonary alveoli and the like. Especially, a high-dose group shows a curative effect superior to that of a positive control drug, and a good dose-effect relationship is combined, so that the preparation has remarkable development potential and clinical transformation prospect in treatment of the septic pneumonia.

A pharmaceutical composition for administering directly to the pulmonary tract of a subject includes a salt of triiodothyronine and a pharmaceutically acceptable buffer, adjusted to a pH of 5.5-8.5. The composition can be administered prophylactically or therapeutically to a subject to treat lung inflammation or pulmonary edema.

Compositions and methods for treating chronic obstructive pulmonary disease, interstitial lung disease, asthma, bronchitis, pneumonia, cystic fibrosis, pulmonary edema, sarcoidosis, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, acute respiratory distress syndrome, and respiratory syncytial virus in a patient are presented. Embodiments of the composition include a combination of diethylcarbamazine (DEC) and a prostacyclin analogue, such as Beraprost, Beraprost sodium, Iloprost, Treprostinil, Treprostinil Palmitil, and Cicaprost. Other embodiments include fluvoxamine and / or a phosphodiesterase (PDE) inhibitor. Some embodiments of the composition are in the form of an aerosol, include a propellent, or are in an inhalation delivery device.

The invention discloses a formula for tonifying kidney and qi and a prevention and treatment effect of a single medicine of the formula in plateau pulmonary edema. The invention provides application of a kidney-tonifying and qi-benefiting formula or a single medicine or an active ingredient thereof in preparation of a medicine for preventing and / or treating plateau pulmonary edema, the kidney-tonifying and qi-benefiting formula is a traditional Chinese medicinal material composed of herba epimedii, radix astragali and radix rehmanniae recen or an extract of the traditional Chinese medicinal material, the single medicine is herba epimedii, and the active ingredient is icariin. According to the present invention, the plateau pulmonary edema rat model is induced through low pressure and low oxygen, and the prevention and treatment effect of the kidney-tonifying qi-benefiting formula and the single drug or the active component thereof on the plateau pulmonary edema is verified in the animal model, such that the new treatment drug is provided for the clinical treatment of the plateau pulmonary edema, and the limitation of the existing treatment drug is hopefully overcome; good application prospects are realized.

The invention relates to application of a sulfonamide compound or a pharmaceutical composition containing the sulfonamide compound in preparation of a medicine for treating pulmonary edema. The medicine has a prominent curative effect on pulmonary edema by inhibiting NKCC1 targets of lungs and is high in safety, so that adverse effects such as electrolyte disorder caused by potent diuretics are reduced, and the medicine is a better new medicine for clinically treating pulmonary edema.

The present invention relates to the field of biological medicines. Disclosed are N-tetrazolyl aryl urea derivatives, a preparation method therefor, and the use thereof. The present invention has recently discovered the N-tetrazolyl aryl urea derivatives, and further found that the compounds have an antagonistic activity against bradykinin B1 receptor, so that the compounds can be used as novel bradykinin B1 receptor antagonists and can be further used for treating or preventing related diseases caused by abnormal expression of the bradykinin B1 receptor. In particular, the present invention has recently found that N-tetrazolyl aryl urea derivatives have prevention or treatment effects on corona virus disease 2019, pulmonary edema, diabetes complications, allergic conjunctivitis, etc.

The invention relates to the technical field of traditional Chinese medicines, and discloses application of donkey-hide gelatin bone-strengthening oral liquid in prevention and treatment of plateau hypoxic polycythemia. The colla corii asini bone-strengthening oral liquid can be used for preparing medicines for reducing the number of red blood cells in the high altitude polycythemia, improving the form and function of the red blood cells in the high altitude polycythemia and improving pulmonary edema and encephaledema caused by the high altitude polycythemia. The colla corii asini bone-strengthening oral liquid is applied to prevention and treatment of the plateau hypoxic polycythemia, and the problems that at present, traditional Chinese medicine formulas for treating the plateau polycythemia clinically are few, and the plateau polycythemia resisting effect is poor can be solved.

The invention provides application of dragon's blood and active ingredients thereof in preparation of a medicine for treating heart failure, and belongs to the technical field of biological medicine. It is found for the first time that the dragon's blood can significantly improve the heart function of a heart failure model animal, reduce the level of a heart failure marker and relieve cardiac hypertrophy, cardiac pulmonary edema, myocarditis infiltration and fibrosis; core active components such as genistein and 3-hydroxycinnamic acid are screened and verified, wherein the genistein can reproduce the overall treatment effect of the dragon's blood. The invention also discloses that the core action mechanism of the composition is to promote macrophage VEGFC secretion, increase heart lymphatic vessel density and promote lymphatic vessel neogenesis, and a brand new natural drug candidate scheme and an intervention strategy are provided for heart failure treatment.

The invention relates to an application of a vasodilatation drug ferric nitrosyl chloride, which belongs to the field of chemistry and chemical engineering and medicine, and is characterized in that the molecular formula of the compound is Fe (NO) Cl3 or Fe (NO) Cl3. MH2O, m is equal to 1-3, and the compound is mainly used for emergency treatment and relieving of hypertensive emergencies and emergency blood pressure reduction. And acute respiratory distress syndrome caused by heart-lung related diseases such as pulmonary arterial hypertension, chronic obstructive pulmonary disease, plateau pulmonary edema, bronchial asthma, stroke and the like.

The invention belongs to the field of respiratory and cardiovascular system disease treatment, and provides application of bletilla striata glycoside in preparation of a medicine for treating or preventing heart failure and pulmonary edema. It is found and proved for the first time that bletilla striata glycoside can remarkably improve heart function indexes of heart failure model mice, relieve pathological injuries of heart and lung tissue, effectively regulate and control arterial blood-gas indexes in a pulmonary edema model, reduce the level of inflammatory factors in alveolar lavage fluid and improve the pathological structure of lung tissue. The medicine can be applied in dosage forms such as oral administration, injection or spray, and the preferable dosage is 2.5-10 mg / kg. The invention provides a multi-target and multi-effect intervention strategy derived from a natural product for heart failure and concurrent or secondary pulmonary edema thereof, and has a remarkable clinical transformation prospect.

Provided in the present disclosure is the use of edaravone and a pharmaceutically acceptable salt thereof in the prevention and / or treatment of acute high-altitude illnesses caused by acute high-altitude hypobaric hypoxia. The acute high-altitude illnesses include, for example, acute mountain sickness (AMS), high-altitude cerebral edema (HACE), and high-altitude pulmonary edema (HAPE). Additionally provided in the present disclosure is the use of edaravone and a pharmaceutically acceptable salt thereof in the prevention and / or treatment of high-altitude pulmonary hypertension (HAPH) and inflammatory responses caused by acute high-altitude hypobaric hypoxia.

The invention relates to application of a mint-derived exosome in preparation of a medicine for treating LPS-induced ARDS. The mint-derived exosome is obtained through PBS solution soaking, wall breaking, differential centrifugation, filtration, ultracentrifugation, sucrose density gradient centrifugation and other treatment. The mint-derived exosome disclosed by the invention not only can relieve histological injury of LPS-induced ARDS mouse lung tissues and improve pulmonary edema, but also can achieve an anti-inflammatory effect on the ARDS mouse lungs, so that the mint-derived exosome can be used for preparing medicines for treating LPS-induced ARDS.

This invention discloses a method and related equipment for constructing an ultrasound diagnostic training model for lung diseases. The method includes: acquiring magnetic resonance imaging (MRI) data of the chest of a target subject; performing three-dimensional reconstruction and structural segmentation on the MRI data to generate a three-dimensional anatomical digital model of the lung, including the lung parenchyma, pleura, diaphragm, ribs, and mediastinal structures; optimizing the structure, layering the model, and annotating material properties using three-dimensional modeling software to generate a three-dimensional printing model file; constructing a physical lung training model based on the three-dimensional printing model file using a multi-material three-dimensional printing device, and setting pathological simulation structures in a preset area of ​​the model to simulate the ultrasound imaging characteristics of diseases such as pulmonary consolidation, pleural effusion, pneumothorax, and pulmonary edema. The training model constructed by this invention has a realistic anatomical structure, is reusable, and can present typical lung ultrasound imaging characteristics under real ultrasound equipment.

This invention relates to the field of biopharmaceutical technology, specifically to the application of dichloroacetate in the preparation of drugs for preventing high-altitude pulmonary edema. This invention is the first to propose and verify the application of dichloroacetate in preventing high-altitude pulmonary edema. By administering dichloroacetate to mice via drinking water three days in advance as a preventative measure, the degree of pulmonary edema was reduced, providing new drug selection and experimental evidence for the prevention and treatment of altitude sickness.

The invention relates to a traditional Chinese medicine preparation for treating hydropneumosis and leg and foot edema and a preparation method thereof. The preparation is prepared from 15g of pinellia ternate stems and leaves, 25g of lysimachia christinae hance stems and leaves, 75g of wild pineapple fruits, 3g of fresh ginger and 3g of liquorice. The preparation method comprises the following steps: adding 1500g of water into the medicinal materials, soaking for 10 minutes, boiling with big fire, decocting with small fire until the medicine liquid is concentrated to 500g, filtering, repeatedly decocting once, and combining the two filtrates to obtain 1000g of medicine juice. The medicine juice is taken three times a day in two days, and clinical observation shows that after a patient continuously takes the medicine juice for 4 days, the effusion reduction rate is remarkable. The preparation has the effects of inducing diuresis to reduce edema and promoting effusion discharge, has no obvious toxic or side effect, and is suitable for hydropneumosis and lower limb edema caused by pneumonia, pulmonary tuberculosis, lupus erythematosus and other diseases.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a modified Zhenwu decoction traditional Chinese medicine compound and application thereof. The traditional Chinese medicine compound of the modified true Wu decoction is prepared from the following raw materials in parts by weight: 10 to 30 parts of radix aconiti lateralis praeparata slices, 6 to 18 parts of sun-dried ginseng, 10 to 30 parts of poria cocos, 8 to 24 parts of raw rhizoma atractylodis macrocephalae, 10 to 30 parts of radix paeoniae alba, 20 to 60 parts of pubescent holly root and 4 to 12 parts of rhodiola rosea. Clinical observation finds that the flavored Zhenwu decoction is an effective drug for resisting HFpEF, and can reverse cardiac hypertrophy of HFpEF mice, relieve pulmonary edema conditions, remarkably improve the diastolic function, improve HFpEF cardiac hypertrophy, improve cardiac diastolic dysfunction, improve myocardial injury and collagen deposition and improve myocardial cell mitochondrial injury.

The invention discloses an application of TRAF7 in screening of anti-lung injury drugs. In an LPS-induced A549 cell acute lung injury model, TRAF7 gene knock-down significantly aggravates cell apoptosis and inflammatory response, which shows that inflammatory factor release is increased, and cell injury is aggravated; and TRAF7 overexpression can obviously inhibit the pathological change. The result shows that the TRAF7 has a protection effect on alveolar epithelial cells, the expression level of the TRAF7 is in negative correlation with the in-vitro lung injury degree, and it is proved that the TRAF7 has a negative regulation effect in acute lung injury. In a mouse ALI model, TRAF7 overexpression can significantly reduce the total number of cells, the total protein content and the wet / dry weight ratio of lung tissue in bronchoalveolar lavage fluid (BALF), relieve the pathological injury score of the lung and inhibit LY6Gneutrophil and CD68 macrophage infiltration. The TRAF7 can effectively relieve LPS-induced pulmonary edema, vascular permeability increase and tissue inflammation, and the anti-inflammatory and tissue protection functions of the TRAF7 in an in-vivo model are verified.

The application discloses an anti-hypoxia radix glabra composite solid beverage and a preparation method thereof, and belongs to the technical field of health-care beverages. The anti-hypoxia radix glabra composite solid beverage is prepared from radix glabra of nine years as raw material, and comprises the following steps: screening and cleaning, twice soaking, 80 DEG C segmented cooking, 70 DEG C gradient concentration, and low-temperature drying at 65 DEG C or below to obtain high-activity radix glabra extract; then, the radix glabra extract is mixed with white sugar and 95% edible alcohol according to a mass ratio of 1:2:1, and the mixture is dried at 50 DEG C for 2 hours, granulated for 1 hour to obtain the solid granular beverage. The anti-hypoxia radix glabra composite solid beverage has the advantages of maximizing the retention of anti-hypoxia active ingredients, improving the taste and solubility, and the like. Animal experiments prove that the product can significantly relieve the weight loss, pulmonary edema and brain edema caused by hypoxia, regulate key indexes such as HIF-alpha, EPO, TNF-alpha, IL-6 and SOD, and has no obvious organ toxicity and high safety when taken for a long time. The anti-hypoxia radix glabra composite solid beverage is suitable for industrial production, can be used for developing health-care food for resisting hypoxia and relieving the plateau reaction, and provides a standardized scheme for high-value utilization of radix glabra.

This invention relates to the field of medical data processing technology, specifically to a lung infection status early warning system based on medical big data. The system captures the flow velocity response before and after expiratory pressure regulation, and uses regularized inversion to deconstruct the time-domain signal, which is disturbed by respiratory rate, into a standardized sequence of measured lung unit volumes. Subsequently, it constructs a theoretical distribution benchmark of purely elastic recoil using measured high-pressure data. By constructing a transmission cost matrix reflecting the shear characteristics of non-Newtonian fluids, it uses an optimal transmission algorithm to calculate the optimal transmission strategy that reshapes the theoretical distribution into the measured distribution. Finally, it analyzes the topological entropy and transmission energy consumption of this transmission strategy to extract obstruction features and generate an early warning. This invention utilizes a rheological model to specifically quantify the viscosity and focal distribution of fluid within the airway, effectively differentiating between physical pulmonary edema and biological airway obstruction at an early stage.

The present invention relates to the use of bacterial compositions having an arginine deiminase activity (inhibition of nitric oxide synthase by conversion of L-arginine to L-citrulline) of 1-1,000 μmol L-citrulline / h / g composition and a sphingomyelinase (ceramide generation) activity of 0.01-1.000 nmoles ceramides / h / g composition in the treatment and / or prophylaxis of airway diseases caused by viruses such as influenza viruses, coronaviruses, as SARS-CoV, MERS-CoV and SARS-CoV-2, avian viruses, respiratory syncytial virus (VRS), rhinoviruses, pneumoviruses, or respiratory failure induced or aggravated by viral infections, angina pectoris, pulmonary heart, respiratory distress, pulmonary edema, neonatal asphyxia, myocardial infarction, heart failure, respiratory failure Pickwick syndrome, pulmonary hypertension, pneumonia or even cystic fibrosis (CF) aggravated by viral infections.

The invention relates to the technical field of medicines, in particular to a pre-carbon monoxide saturated hemoglobin oxygen carrier preparation as well as a preparation method and application thereof in resisting pulmonary fibrosis. The preparation method of the pre-carbon monoxide saturated hemoglobin oxygen carrier preparation comprises the following steps: carrying out carbon monoxide saturation treatment on the hemoglobin oxygen carrier preparation; the carbon monoxide saturation treatment comprises the step of introducing carbon monoxide for 15-25 minutes at the temperature of 2-6 DEG C and the speed of 0.5-1.5 L / min. The pre-carbon monoxide saturated hemoglobin oxygen carrier preparation can significantly reduce bleomycin induced pulmonary edema and injury, improve the pulmonary hypoxia state and inhibit the pulmonary fibrosis process, and provides a brand new treatment strategy for clinical treatment of pulmonary fibrosis.

The present invention relates to systems and methods for monitoring impedance from a sensor in the chest of a subject to determine the status of lung inflation or presence of pneumothorax in the subject, the presence of pulmonary edema, the status of regional lung ventilation, and the status of cardiac contractility.